FIELD: medicine.
SUBSTANCE: invention refers to medicine, and aims at treating excessive daytime sleepiness (EDS). It involves introducing a therapeutically effective amount of an enantiomer (R) betaaminobenzopropyl urethane or an enantiomer compound in which the enantiomer (R) prevails.
EFFECT: method allows prolonging active waking and extending deep sleep.
6 cl, 4 tbl, 1 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD OF TREATING FIBROMYALGIA SYNDROME | 2010 |
|
RU2557533C2 |
| APPLICATION OF FLECAINIDE AS ANTICONNEXIN AGENT AND METHOD OF POTENTIATION OF EFFECTS OF PSYCHOTROPIC MEDICINES | 2014 |
|
RU2661026C2 |
| NEW COMBINATIONS OF H3 RECEPTOR ANTAGONISTS AND NOREPINEPHRINE REUPTAKE INHIBITORS AND THEIR THERAPEUTIC USE | 2019 |
|
RU2809163C2 |
| METHODS FOR TREATING AND PREVENTING FATIGUE | 2010 |
|
RU2567801C2 |
| CATAPLEXIS TREATMENT | 2014 |
|
RU2689984C2 |
| USE OF AN INVERSE AGONIST H3R FOR TREATING SLEEP DISORDER IN SHIFT WORK | 2018 |
|
RU2768894C2 |
| COMPOUNDS USED FOR SLEEP/WAKEFULNESS CYCLE NORMALISATION | 2003 |
|
RU2366428C2 |
| H3-LIGAND TETRAHYDRATE, ITS PRODUCTION METHOD, AND PHARMACEUTICAL COMPOSITIONS CONTAINING IT | 2018 |
|
RU2771753C2 |
| USING MIRTAZAPINE FOR TREATMENT OF SLEEP DISORDER | 2001 |
|
RU2270680C2 |
| USE OF INVERSE AGONISTS OR ANTAGONISTS OF GHRELIN RECEPTOR FOR TREATING SLEEP DISORDERS | 2013 |
|
RU2600895C2 |
